Madrigal Pharmaceuticals Inc

Portfolio0% of Portfolio

Price Gain

Dividends

Returns

Investors19 holders & 6 watchers

Market MovesTrades in the last 30 days

1 Bought

1 Sold

Financials

Market Cap$12B

Dividend Yield0.00%

P/E Ratio--

EPS-13.98

Volume153K

Beta-0.99

MER--

AUM$0.00

About

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.